propofol + fentanyl + sevoflurane + remifentanil + rocuronium

This entry refers to a specific multi-drug general anesthetic regimen utilized in clinical research conducted by Cardiocentro Ticino, notably in the ANESTOX-2019 study. The regimen consists of a combination of the intravenous sedative-hypnotic propofol, the volatile inhalational anesthetic sevoflurane, the opioid analgesics fentanyl and remifentanil, and the non-depolarizing neuromuscular blocking agent rocuronium. This combination is being evaluated to determine the association between general anesthesia exposure and perioperative changes in plasma Neurofilament Light (NfL) levels, which serve as a biomarker for axonal injury. The research aims to assess the potential neurotoxic effects of these agents and their correlation with the development of postoperative neurocognitive disorders, such as acute delirium, particularly in patients undergoing cardiac device implantation.

Other names

general anesthetic-Cardiocentro TicinoGeneral anesthetic (propofol, fentanyl, sevorane, remifentanyl, rocuronium)ANESTOX-2019 anesthetic regimenANESTOX2019 anesthetic regimenANESTOX 2019 anesthetic regimen